Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 5/2007

01-10-2007 | Commentary

Activated protein C: cost-effective or costly?

Authors: Savtaj Singh Brar, Braden J Manns

Published in: Critical Care | Issue 5/2007

Login to get access

Abstract

The authors offer a commentary on the study by Dhainaut et al. on the cost-effectiveness of activated protein C in severe sepsis. Using data from "real world" conditions, the results of this economic evaluation are consistent with previous analyses, and highlight the need for "real world" investigations of new health technologies in critical care.
Literature
1.
Dhainaut J-F, Payet S, Vallet B, Riou-França L, Annane D, Bollaert P-E, Le Tulzo Y, Runge I, Malledant Y, Guidet B, et al.: Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 2007, 11: R99. 10.1186/cc6116PubMedCentralCrossRefPubMed
2.
Cox HL, Laupland KB, Manns BJ: Economic evaluation in critical care medicine. J Crit Care 2006, 21: 117-124. 10.1016/j.jcrc.2006.02.003CrossRefPubMed
3.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
4.
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31: 1-11. 10.1097/00003246-200301000-00001CrossRefPubMed
5.
Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW: An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics 2003, 21: 1331-1340. 10.2165/00019053-200321180-00004CrossRefPubMed
6.
Green C, Dinnes J, Takeda AL, Cuthbertson BH: Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 2006, 22: 90-100.CrossRefPubMed
7.
Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C: An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347: 993-1000. 10.1056/NEJMsa020969CrossRefPubMed
8.
Riou Franca L, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, Guidet B: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care 2006, 22: 101-108.PubMed
9.
Revicki DA, Frank L: Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999, 15: 423-434. 10.2165/00019053-199915050-00001CrossRefPubMed
10.
Sculpher MJ, Claxton K, Drummond M, McCabe C: Whither trial-based economic evaluation for health care decision making? Health Econ 2006, 15: 677-687. 10.1002/hec.1093CrossRefPubMed
11.
Drummond M, Mason A, Towse A: The desirability and feasibility of economic studies of drugs post-launch. Eur J Health Econ 2006, 7: 5-6. 10.1007/s10198-006-0337-2CrossRefPubMed
12.
Mackenzie AF: Activated protein C: do more survive? Intensive Care Med 2005, 31: 1624-1626. 10.1007/s00134-005-2829-4CrossRefPubMed
13.
Wiedermann CJ: When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated). Intensive Care Med 2006, 32: 604. 10.1007/s00134-006-0086-9CrossRefPubMed
Metadata
Title
Activated protein C: cost-effective or costly?
Authors
Savtaj Singh Brar
Braden J Manns
Publication date
01-10-2007
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc6090

Other articles of this Issue 5/2007

Critical Care 5/2007 Go to the issue

Research

How to evaluate the microcirculation: report of a round table conference

Research

Improved survival of children with sepsis and purpura: effects of age, gender, and era

Research

Multiple organ failure after trauma affects even long-term survival and functional status

Review

Bench-to-bedside review: Developmental influences on the mechanisms, treatment and outcomes of cardiovascular dysfunction in neonatal versus adult sepsis

Journal club critique

Albumin and furosemide for acute lung injury

Research

Intentional overdose with insulin: prognostic factors and toxicokinetic/toxicodynamic profiles